Effects of administration of fostamatinib on blood concentrations of rifampicin in healthy subjects.
Study identifier:D4300C00015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-Label, Non-Randomized, 2-Period, Single Center Study to Assess the Single Dose Pharmacokinetics of R406 in Healthy Subjects when Fostamatinib 150 mg is Administered Alone and in Combination with Rifampicin
Medical condition
Rheumatoid Arthritis, Healthy Volunteers
Phase
Phase 1
Healthy volunteers
Yes
Study drug
fostamatinib, rifampicin
Sex
All
Actual Enrollment
15
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 Apr 2011
Primary Completion Date: 01 Jul 2011
Study Completion Date: 01 Jul 2011
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Fostamatinib | Drug: fostamatinib oral tablets, 150mg (3 X 50mg) single dose per period |
| Experimental: 2 Rifampicin | Drug: fostamatinib oral tablets, 150mg (3 X 50mg) single dose per period Drug: rifampicin oral tablets, 600mg (2 X 300mg) 8 doses over 8 days |
